New Delhi: Pharma major Lupin Limited announced that its corporate social responsibility (CSR) arm, the Lupin Foundation won the prestigious award for ‘Excellence in Corporate Social Responsibility’ at the India Pharma Awards 2019 held in Greater Noida (National Capital Region). Lupin was conferred this award in the category for companies with turnover more than INR 500 Cr. The jury panel, represented by various segments of the Indian Pharmaceutical Industry chose the Lupin Foundation for its unwavering commitment and efforts to uplift the rural population in remote areas across India through initiatives focused on socio-economic improvement and women and children welfare.
Commenting on the occasion, Shri Sita Ram Gupta, Executive Director, Lupin Foundation said, “It is an honour to be bestowed with this prestigious award. As a frontrunner in the CSR space, we strive to give back to society and make a positive impact. This award acknowledges the organisation’s commitment towards society. Such recognitions also encourage us to deepen our CSR footprint — continually building on the vision provided by our beloved founder , Dr. Desh Bandhu Gupta.”
Currently in its seventh year, the India Pharma Awards celebrates the advancements and achievements of the Indian Pharmaceutical Industry. The event was a part of the India Pharma Week 2019 held in Greater Noida (National Capital Region) between 26 – 28 November, 2019 and recognises companies and personnel from this industry.
About Lupin Foundation
Lupin Foundation is a trust, NGO, independent body promoted by Lupin Ltd. Formed in 1988, decades before CSR became mandatory, showing its commitment beyond just compliance. The vision of Lupin Foundation is to see Indian villages not only economically prosperous but as centres of prosperity consciousness integrating leading corporate houses, planners, technologists and development oriented people having stewardship which is spiritual in Vision, scientific in temper and humanistic in Karma.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); 6th largest company in the Indian Pharmaceutical Market and 5th largest generic pharmaceutical player in Japan (IQVIA MAT September 2019).
For the financial year ended March 31, 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055
For further information or queries please contact –
Head – Investor Relations and M&A / Corporate Communications